GI
CRBP icon

Gradient Investments’s Corbus Pharmaceuticals CRBP Stock Holding History

Gradient Investments’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed – – 1010
2018
Q1 		$0 Hold
1
– – ﹤0.01% 1029
2017
Q4 		$0 Buy
+1
New +$214 ﹤0.01% 1018

Other funds holding CRBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Gradient Investments's CRBP Position: Q2 2018 in Review

Gradient Investments sold out of Corbus Pharmaceuticals (CRBP) in Q2 2018, closing a stake of 1 share.

Gradient Investments first reported a position in CRBP in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 82 funds tracked by Wall St. Rank hold CRBP as of Q2 2018.

  • Gradient Investments reported no remaining Corbus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Gradient Investments sold 1 Corbus Pharmaceuticals share in Q2 2018.
  • Gradient Investments first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Gradient Investments's Corbus Pharmaceuticals position peaked at $0 in Q1 2018.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2018.

Based on Gradient Investments's 13F filing for Q2 2018, filed 9 Aug 2018.